Search Site

David J. Cohen, MD

  • Professor of Medicine at CUMC
  • Medical Director, Renal Transplantation
David J. Cohen, MD

I am involved in numerous clinical protocols investigating new immunosuppressive drugs and/or new combinations of existing medications in renal transplant patients, both newly transplanted patients and those with long-term functioning transplants.

I am interested in immunosuppressive drug protocols in renal transplantation, as well as renal disease occurring in recipients of non-renal transplants.

Languages Spoken

  • French

Education & Training

  • Albert Einstein College of Medicine - Yeshiva University
  • Internship: Mount Sinai Hospital
  • Residency: Mount Sinai Hospital
  • Fellowship: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Fellowship: Brigham & Women's Hospital

NIH Grants

  • EVALUATION OF POTENTIAL PREDICTORS OF DISEASE PROGRESSION IN PATIENTS WITH AHUS, INCLUDING GENETICS, BIOMARKERS, AND TREATMENT (P&S Industry Clinical Trial)

    Aug 1 2017 - Aug 1 2022

    OBSERVATIONAL STUDY PROTOCOL IM103076 EVALUATING NULOJIX LONG TERM SAFETY IN TRANSPLANT ENLIST REGISTRY (P&S Industry Clinical Trial)

    Aug 14 2013 - Aug 14 2018

    A PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF MCMV5322A/MCMV3068A FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN HIGH-RISK KIDNEY ALLOGRAFT RECIPIENTS (P&S Industry Clinical Trial)

    Feb 8 2013 - Feb 8 2018

    DRUG LEVEL VARIABILITY IN CHILDREN AFTER RENAL TRANSPLANT AND TRANSITION OF CARE (Federal Gov)

    Jul 1 2015 - Jun 30 2016

    C10-004 (P&S Industry Clinical Trial)

    Jun 23 2011 - Jun 23 2016

    NATURAL HISTORY OF INFECTION CAUSED BY BK VIRUS (AND OTHER OPPORTUNISTIC VIRAL PATHOGENS ) IN RENAL AND RENAL-PANCREAS TRANSPLANT RECIPIENTS (Federal Gov)

    Oct 1 2013 - Sep 27 2015

    A 12 MONTH, MULTI-CENTER, RANDOMIZED, OPEN-LABEL NONINFERIORITY STUDY COMPARING THE SAFETY AND EFFICACY OF CONCENTRATION (P&S Industry Clinical Trial)

    Sep 14 2010 - Sep 14 2015

    A PHASE 3, OPEN-LABEL,MULTICENTER,PROSPECTIVE, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF CONVERTING STABLE KIDNEY T (P&S Industry Clinical Trial)

    Mar 18 2009 - Sep 30 2014

    PLANNED TRANSITION TO SIROLIMUS-BASED THERAPY VERSUS CONTINUED TACROLIMUS-BASED THERAPY IN RENAL ALLOGRAFT RECIPIENTS (P&S Industry Clinical Trial)

    Jul 22 2009 - Jul 22 2014

    AN OPEN LABEL, MULTICENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADULT PATIENTS WITH PLASMA THERAPY-RESISTANT ATYPI (P&S Industry Clinical Trial)

    Jun 25 2009 - Jun 25 2014

    LCP TOCRO 2017 (P&S Industry Clinical Trial)

    Nov 12 2008 - May 31 2014

Publications

  • Wilkinson AH, Cohen DJ. (1999) Renal failure in recipients of non-renal solid organ transplants. J Amer Soc Nephrol 10:1136-45
  • The Mycophenolate Mofetil Acute Rejection Study Group. (2001) Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. Transplantation 71:1091-7
  • Lin J, Valeri AM, Cohen DJ, Radhakrishnan J. (2002) Angiotensin converting enzyme (ACE) inhibition in chronic allograft nephropathy. Transplantation 73:783-8
  • Adams PL, Cohen DJ, Danovitch GM, et al. (2002) The nondirected live-kidney donor: ethical considerations and practice guidelines. Transplantation 74:582-90

For a complete list of publications, please visit PubMed.gov